Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European Regulators.

Holtkamp, Frank; Gudmundsdottir, Hrefna; Maciulaitis, Romaldas; Benda, Norbert; Thomson, Andrew; Vetter, Thorsten

Holtkamp, Frank; Gudmundsdottir, Hrefna; Maciulaitis, Romaldas; Benda, Norbert; Thomson, Andrew; Vetter, Thorsten.

Afiliação

Holtkamp F; Dutch Medicines Evaluation Board, Utrecht, the Netherlands.
Gudmundsdottir H; Icelandic Medicines Agency, Reykjavík, Iceland; Landspitali - The National University Hospital of Iceland, Reykjavík, Iceland.
Maciulaitis R; Institute of Physiology and Pharmacology, Lithuanian University of Health Sciences, Kaunas, Lithuania; Lithuanian State Medicines Control Agency, Kaunas, Lithuana.
Benda N; German Federal Institute for Drugs and Medical Devices, Bonn, Germany.
Thomson A; European Medicines Agency, Amsterdam, the Netherlands.
Vetter T; European Medicines Agency, Amsterdam, the Netherlands. Electronic address: thorsten.vetter@ema.europa.eu.

Am J Kidney Dis ; 75(1): 6-8, 2020 01.

Article em En | MEDLINE | ID: mdl-31672251

Assuntos

Albuminúria; Insuficiência Renal Crônica; Taxa de Filtração Glomerular; Humanos; Rim; Estados Unidos; United States Food and Drug Administration

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Albuminúria / Insuficiência Renal Crônica Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google